New paper identifies how PVSRIPO stimulates antitumor immunity

By The Science Advisory Board staff writers

March 25, 2021 -- A new study published in Nature Communications found that intratumoral PVSRIPO therapy through unique activation of antigen-presenting cells in the tumor microenvironment stimulates functional CD8+ T-cell responses, leading to systemic antitumor immunity.

PVSRIPO is an investigational immunotherapy based on the live-attenuated Sabin type 1 poliovirus vaccine developed by Istari Oncology. PVSRIPO has a distinct target (the poliovirus receptor CD155), which is widely expressed in neoplastic cells of most solid tumors.

According to the preclinical data, PVSRIPO triggers sustained type 1/III interferon secretion with minimal release of unwanted cytokines.

The company is preparing to evaluate PVSRIPO in a phase II clinical study to determine its ability to generate a systemic immune response in melanoma tumors and suppress cancer growth.

Istari wins orphan drug designation for melanoma therapy
The U.S. Food and Drug Administration has granted orphan drug designation to Istari Oncology for its PVSRIPO technology as a treatment for stage IIB-IV...
New immunotherapy piggybacks off polio vaccine to treat cancer
As if we needed another reason to get vaccinated, researchers have developed a technology that leverages the polio vaccine to help treat cancer for those...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter